Impressive response to denosumab in a patient with bone metastatic adenocarcinoma of the stomach after 2 years of zoledronic acid

Alessandro Cappetta, Laura Spano, Laura Evangelista, Stefania Zovato, Giuseppe Opocher, Davide Pastorelli

Research output: Contribution to journalArticlepeer-review

Abstract

Bone is a common site for tumor spread in patients with solid tumors. So far bisphosphonates have been the main pharmacological treatment option for patients with bone metastases. We present a case of bone metastatic gastric cancer treated with zoledronic acid at first and later with denosumab. After 1 year of denosumab treatment, the 18F-fluorodeoxyglucose (18F-FDG)-PET/computed tomography scan reassessment documented a metabolic complete response, even in the absence of specific antiblastic treatment. Whether denosumab can be used directly after pretreatment with bisphosphonates has yet to be addressed.

Original languageEnglish
Pages (from-to)232-235
Number of pages4
JournalAnti-Cancer Drugs
Volume26
Issue number2
DOIs
Publication statusPublished - Feb 1 2015

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Impressive response to denosumab in a patient with bone metastatic adenocarcinoma of the stomach after 2 years of zoledronic acid'. Together they form a unique fingerprint.

Cite this